Biolight (BOLT) AI Stock Analysis

• Market Cap: ₪30.68M
• Dividend Yield: N/A
• Average Volume (3M): 11.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: -46.97%
• EPS Growth: -127.67%
• Country: IL
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,047,603
• 10 Day Avg. Volume: 7,448
• 30 Day Avg. Volume: 11,863
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: 320.00 ▼(-13.84% Downside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is held down primarily by weak financial performance (minimal/volatile revenue, persistent losses, and ongoing negative free cash flow). Technicals add further pressure with the stock trading below major moving averages and a negative MACD. Valuation is also challenged due to losses and no dividend yield support.

Positive Factors

Low leverage / balance-sheet resilience

Very low debt materially reduces refinancing and solvency risk, giving the company more time to execute strategic options. This structural strength improves flexibility for fundraising, partnerships, or restructuring and helps preserve optionality while operations are improved.

Lean cost structure (very small headcount)

A four-person workforce implies a structurally low fixed payroll burden, which can extend cash runway and allow management to allocate scarce capital to critical R&D or regulatory milestones. The lean structure supports operational flexibility during funding gaps.

Lower market volatility exposure (low beta)

A beta well below 1 suggests lower sensitivity to broad market swings, reducing the risk of market-driven funding stress. That structural lower volatility can aid steadier access to capital and lessen financing disruption during market downturns.

Negative Factors

Immaterial and volatile revenue, zero in 2025

Volatile and effectively nonexistent revenue destroys the company’s ability to self‑fund growth or prove commercial product-market fit. Structural reliance on external capital persists until recurring, material revenue is established, increasing long-term execution risk.

Consistent negative operating and free cash flow

Persistent negative operating and free cash flow indicate ongoing cash burn that will require repeated external financing or significant cost reduction. This undermines long-term investment capacity and raises dilution and solvency risks absent a durable revenue ramp.

Persistent deep losses and negative returns on equity

Ongoing deep losses erode equity and impair credit profiles, limiting strategic options. Negative ROE across years signals the company is consuming shareholder capital rather than generating it, making sustainable growth and partner confidence harder to achieve.

Biolight Business Overview & Revenue Model

Company Description

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.

Biolight Financial Statement Overview

Summary

Balance sheet strength (low leverage) is outweighed by very weak operations: immaterial/volatile revenue (including zero revenue in 2025), persistent deep losses, and ongoing negative operating and free cash flow indicating sustained cash burn and potential future funding needs.

Income Statement

Revenue remains immaterial and volatile, culminating in zero revenue in 2025, which drove negative gross profit and a severe deterioration in operating results. Losses are persistent across the period, with EBIT and net income deeply negative in every year except 2021, indicating the business has not reached a sustainable earnings model. While 2024 showed modest revenue versus prior years, the overall trajectory is dominated by high operating losses and weak profitability.

Balance Sheet

The balance sheet is a relative strength: leverage is very low (debt is small versus equity across the years), which reduces refinancing and solvency risk. However, profitability remains a key issue, with consistently negative returns on equity in recent years, signaling that the equity base is being consumed by ongoing losses. Assets and equity have also declined versus earlier periods, pointing to gradual balance-sheet erosion despite limited debt.

Cash Flow

Cash generation is weak, with operating cash flow consistently negative and free cash flow also negative every year shown, indicating ongoing cash burn. Free cash flow changes year-to-year are mixed but do not show a sustained improvement trend. Cash burn broadly tracks reported losses (free cash flow roughly in line with net income in several years), which suggests limited near-term relief without a material revenue ramp or cost reset.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	219.00K	118.00K	63.00K	3.00K
Gross Profit	-544.00K	219.00K	118.00K	63.00K	3.00K
EBITDA	-14.66M	-7.75M	-10.60M	-8.03M	-1.31M
Net Income	-11.73M	-7.14M	-26.02M	-7.85M	382.00K
Balance Sheet
Total Assets	42.41M	34.12M	33.45M	57.01M	64.17M
Cash, Cash Equivalents and Short-Term Investments	23.65M	13.47M	8.64M	17.63M	33.71M
Total Debt	772.00K	599.00K	91.00K	527.00K	443.00K
Total Liabilities	2.24M	3.38M	3.15M	3.32M	2.75M
Stockholders Equity	34.40M	26.88M	29.78M	53.17M	60.70M
Cash Flow
Free Cash Flow	-10.86M	-11.02M	-10.99M	-9.64M	-10.65M
Operating Cash Flow	-10.85M	-10.99M	-9.58M	-9.54M	-10.03M
Investing Cash Flow	-16.17M	7.55M	-1.95M	-10.55M	13.48M
Financing Cash Flow	21.37M	7.98M	3.25M	-485.00K	915.00K

Biolight Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 371.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Negative. The current price of 371.4 is above the 20-day moving average (MA) of 335.39, above the 50-day MA of 350.35, and below the 200-day MA of 433.73, indicating a bearish trend. The MACD of -4.44 indicates Negative momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 39.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BOLT.

Biolight Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CANF	54 Neutral	₪22.70M	-4,037.78	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	46 Neutral	₪39.16M	-4.21	―	―	-42.69%	88.04%
BOLT	44 Neutral	₪30.68M	-0.94	―	―	-46.97%	-127.67%
PPBT	43 Neutral	₪18.58M	-0.13	―	―	―	89.32%